Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

BioScience Health Innovations (BHIC) EBITDA (2020 - 2026)

BioScience Health Innovations has reported EBITDA over the past 7 years, most recently at -$229907.0 for Q1 2026.

  • Quarterly EBITDA fell 153.87% to -$229907.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$467683.0 through Mar 2026, down 192.73% year-over-year, with the annual reading at $189022.0 for FY2025, 681.79% up from the prior year.
  • EBITDA was -$229907.0 for Q1 2026 at BioScience Health Innovations, up from -$686698.0 in the prior quarter.
  • Over five years, EBITDA peaked at $457704.0 in Q2 2025 and troughed at -$686698.0 in Q4 2025.
  • The 5-year median for EBITDA is -$38376.0 (2023), against an average of -$22056.2.
  • Year-over-year, EBITDA tumbled 1392.18% in 2022 and then soared 899.53% in 2025.
  • A 5-year view of EBITDA shows it stood at -$28917.0 in 2022, then crashed by 32.71% to -$38376.0 in 2023, then tumbled by 37.76% to -$52865.0 in 2024, then crashed by 1198.97% to -$686698.0 in 2025, then soared by 66.52% to -$229907.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's EBITDA are -$229907.0 (Q1 2026), -$686698.0 (Q4 2025), and -$8782.0 (Q3 2025).